2:00 PM ET
Earnings Call
▶ Call
Teva Pharmaceutical Industries Earnings Call: Key Takeaways
Teva is successfully transitioning to a biopharma model, raising 2026 revenue guidance to $16.7B-$17B and achieving investment-grade status while scaling innovative products like Austedo and Uzedy.
- Call
- Nov 3, 2026, 8:00 AM ET